Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 6/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078710 | 0.90 | HTR2A (0.39) | AOC3HRH1CXCR4HTR2ACHRNA7 | |
| SCHEMBL3081194 | 0.83 | AOC3 (0.43) | AOC3CXCR4HTR2AALOX5APFEN1 | |
| SCHEMBL5489047 | 0.79 | L3MBTL1 (0.40) | AOC3HTR2AALOX5APFEN1 | |
| SCHEMBL3082743 | 0.79 | HRH1 (0.46) | CYP2A6HRH1CXCR4CHRNA7 | |
| SCHEMBL3360283 | 0.78 | CYP2A6 (0.40) | CYP2A6HRH1CXCR4HTR2ACHRNA7 | |
| SCHEMBL3086519 | 0.77 | SLC22A12 (0.35) | CXCR4 | |
| SCHEMBL3079212 | 0.77 | ALDH1A1 (0.48) | AOC3CXCR4 | |
| SCHEMBL3068375 | 0.77 | AOC3 (0.33) | AOC3 | |
| SCHEMBL3081118 | 0.73 | SLC22A12 (0.36) | AOC3CXCR4 | |
| SCHEMBL14959709 | 0.71 | PDE5A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| CN-101835777-A | Carbacephem beta-lactam antibiotics | ACHAOGEN INC | 2010-09-15 | — | — | CN | disclosed |
| EP-2205600-A1 | CARBACEPHEM ß -LACTAM ANTIBIOTICS | Achaogen, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030811-A2 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009055696-A1 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055696-A1 | CARBACEPHEM β-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | CYP2A6 506/4885AOC3 4144/4885HRH1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.